Contract Title: CTU: Novo Nordisk Pharmaceuticals Addendum #1 to the CTRA - NN9838-4942 - The cardiovascular safety and efficacy of cagrilintide 2.4 mg s.c. in combination with semaglutide 2.4 mg s.c. (CagriSema 2.4 mg/2.4 mg s.c.) once-weekly in participants with established cardiovascular disease

Primary Chief Investigator: DR Veronica Preda

Pure Award ID: 278070426, 278070426